Business context and reporting period
Fate Therapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2021. It is a clinical-stage biotechnology company developing off-the-shelf cancer cell therapies derived from engineered induced pluripotent stem cells (iPSCs). It has no approved products and generated no therapeutic-product sales or royalties; reported revenue came from collaborations.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Collaboration revenue | $55.8 million | $31.4 million |
| Research and development expense | $215.5 million | $125.6 million |
| General and administrative expense | $57.3 million | $33.9 million |
| Operating loss | $217.0 million | $128.1 million |
| Net loss | $212.2 million | $173.4 million |
| Net loss per share, basic and diluted | $2.24 | $2.10 |
| Cash used in operating activities | $162.9 million | $39.2 million |
Revenue increased 77.7%, while R&D and G&A expenses rose substantially as the company expanded clinical development, manufacturing, and staffing. Net loss increased despite a year-over-year improvement in other income: 2021 included a $3.5 million gain from remeasurement of MSK stock-price appreciation milestones, versus a $47.7 million expense in 2020. As a development-stage company with no product sales, operating margins are not meaningful.
At year-end, cash and cash equivalents were $133.6 million and investments were $583.0 million, totaling $716.6 million; restricted cash of $15.2 million is separate. Total assets were $921.5 million and stockholders’ equity was $678.8 million. The company reported no outstanding debt; it did have $114.8 million of recorded operating lease liabilities, with $192.6 million in undiscounted future lease payments. Management stated existing cash, cash equivalents, and investments should fund projected requirements for at least 12 months from the filing’s issuance. Financing cash flow was $453.1 million, primarily from the January 2021 equity offering and pre-funded warrants, which generated $432.4 million net proceeds.
Material changes versus the prior year
- Operating cash use rose to $162.9 million from $39.2 million, reflecting increased spending and the absence of the $50.0 million Janssen upfront cash payment received in 2020; Fate also paid MSK $20.0 million after reaching a stock-price milestone.
- R&D expense increased $89.9 million, mainly from employee costs, laboratory materials and supplies, and third-party and clinical-trial expenses. G&A expense increased $23.4 million, including higher compensation and costs associated with the new headquarters.
- Cash, cash equivalents, and investments grew to $716.6 million from approximately $482.9 million, supported principally by equity financing, despite higher operating and investing cash use.
- The company completed its move to a new San Diego headquarters and manufacturing site; property and equipment rose to $91.5 million from $32.3 million.
Outlook, commentary, and principal risks
No formal revenue or earnings guidance was provided. Management expects losses and expenses to continue and increase as clinical trials, preclinical work, and manufacturing scale-up proceed. Additional capital will be required to develop candidates and potentially commercialize products; future financing may dilute shareholders or be unavailable on acceptable terms.
Pipeline progress included FT516 receiving FDA RMAT designation for relapsed/refractory diffuse large B-cell lymphoma. The filing also reported preliminary Phase 1 results for FT516 and FT596 in B-cell lymphoma and FT538 in AML. These were small, early-stage studies; results may change with additional follow-up, patient enrollment, and verification, and do not establish efficacy or approval prospects. Fate reported no dose-limiting toxicities in the cited FT516 and FT596 interim datasets, but safety and effectiveness remain unproven.
Key risks include clinical and regulatory failure; the novel and uncertain iPSC and gene-editing technologies; manufacturing scale, consistency, and third-party supply constraints; trial enrollment and execution delays, including COVID-19 effects; dependence on collaborators; competition; intellectual-property challenges; and continued losses and financing needs. The company also has substantial long-term lease commitments and a $24.2 million year-end liability for remaining MSK stock-price appreciation milestones. No material legal proceedings were reported. The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Track cash burn against the $716.6 million year-end cash-and-investment balance and management’s stated runway; confirm how trial and manufacturing spending affects financing needs.
- Review updated, audited clinical data for FT516, FT596, and other candidates, including durability, follow-up, adverse events, and the impact of larger patient groups.
- Monitor whether RMAT designation leads to a defined late-stage development plan; designation does not guarantee accelerated approval or approval.
- Assess manufacturing capacity, quality, supply-chain resilience, and the ability to transfer or scale production to support later-stage trials.
- Confirm collaboration milestones, option decisions, and cash receipts; milestone and royalty amounts are contingent and are not assured revenue.
- Reconcile future financing and dilution, MSK milestone remeasurement and payments, and long-term lease obligations.